poisar

Stocks · News reference

Elicio Therapeutics Announces Positive Phase 2 AMPLIFY-7P Results for Camupepimut

Fiscal.ai

Elicio Therapeutics reported positive results from its randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) for the treatment of KRAS-driven pancreatic cancer, showing a significant reduction in the risk of recurrence or death.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncDelveinsight

    Cancer Vaccines Clinical Trial Pipeline Boom as 200+ Companies are in the Race for Better Treatments | DelveInsight

    Over 200 companies are advancing cancer vaccine development with 200+ pipeline candidates in clinical trials. Recent positive Phase III results for intismeran autogene (mRNA-4157) in melanoma and encouraging data for TG4050 in head and neck cancer are driving momentum. However, challenges including clinical efficacy uncertainties, manufacturing complexity, high production costs, and patient selection barriers remain obstacles to broader commercialization.